Association of antibiotic-consumption patterns with the prevalence of hematological malignancies in European countries

被引:0
作者
Gábor Ternák
Károly Berényi
Balázs Németh
Ágnes Szenczi
Gergely Márovics
István Kiss
机构
[1] University of Pécs,Institute of Migration Health
[2] Medical School,Department of Public Health Medicine
[3] University of Pécs,undefined
[4] Medical School,undefined
来源
Scientific Reports | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hematological malignancies are considered the fifth most common cancer in the world. Several risk factors and probable etiological agents have been suspected in the pathomechanism of those malignancies as infections, chemicals, irradiation, etc., and recently, the contribution of the altered gut flora, dysbiosis, was identified also as a possible additional factor to the existing ones. Host, and external factors, like antibiotics, which were identified as a major disruptor of the "normal" gut flora, influence the composition of the microbiome. Considering the several-fold differences in antibiotic consumption patterns and the incidence of hematological malignancies in European countries, the hypothesis was raised that the dominant consumption of certain antibiotic classes might influence the incidence of different hematological malignancies through the modification of gut flora. Comparisons were performed between the average antibiotic consumption databases reported yearly by ECDC (2009–2019) and the incidence rate of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and leukemia (LEU) estimated for 2020 in 30 European countries. Applying Spearman calculations, significant positive correlation has been found between the incidence of HL and tetracycline (J01A) consumption (r = 0.399, p = 0.029), NHL and narrow spectrum, beta-lactamase resistant penicillin (J01CF) (r = 0.580, p = 0.001), MM and tetracycline (r = 0.492, p = 0.006), penicillin (J01C) (r = 0.366, p = 0.047), narrow spectrum, beta-lactamase resistant penicillin (J01CF) (r = 0.574, p = 0.001), while strong, significant negative correlation has been recorded between NHL and cephalosporin (r = − 0.460, p = 0.011), and quinolone (r = − 0.380, p = 0.038). The incidence of LEU did not show any positive or negative association with any antibiotic classes using Spearman calculation. Multivariate ordinal logistic regression (OR) indicated increased risk between HL and the total consumption of systemic antibiotics (J01 p: 0.038), and tetracyclin (J01A p: 0.002). Similarly, increased risk has been detected between the MM and tetracyclin (J01A p: 0.02), and narrow spectrum, beta-lactamase resistant penicillin (J01CF p: 0.042) and decreased risk between cephalosporin and MM (J01D p:0.022). LEU showed increased risk with the consumption of macrolides (p: 0.047).
引用
收藏
相关论文
共 221 条
[1]  
Fitzmaurice C(2018)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life- years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study JAMA Oncol. 4 1553-1568
[2]  
Akinyemiju TF(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 71 209-249
[3]  
Al Lami FH(2020)Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis Lancet Glob. Health. 8 e180-e190
[4]  
Alam T(2008)Chronic lymphocytic leukemia Lancet 371 1017-1029
[5]  
Alizadeh-Navaei R(2014)Diagnosed hematological malignancies in Bangladesh—A retrospective analysis of over 5000 cases from 10 specialized hospitals BMC Cancer 14 438-544
[6]  
Allen C(2021)Gut microbiota influence in hematological malignancies: From genesis to cure Int. J. Mol. Sci. 22 1026-e24
[7]  
Alsharif U(2015)New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy Expert Rev. Anticancer Ther. 15 531-3764
[8]  
Alvis-Guzman N(2018)Epidemiological patterns of leukaemia in 184 countries: A population-based study Lancet Hematol. 5 e14-287
[9]  
Amini E(2016)A review of risk factors for childhood leukemia Eur. Rev. Med. Pharmacol. Sci. 20 3760-567
[10]  
Sung H(2016)Non-Hodgkin's lymphoma Nurs. Stand. 31 15-596